stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Total debt
Tarsus Pharmaceuticals, Inc.'s total debt at the end of fiscal 2025 was $72.4M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $72.9M. Over the past ten years it has ranged from $100.0K (fiscal 2019) to $72.4M (fiscal 2025) — the current reading is the highest in ten years. Tarsus Pharmaceuticals, Inc. ranks 111th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $72.4M | 0.83% |
| FY2024 | $71.8M | 140.94% |
| FY2023 | $29.8M | 53.44% |
| FY2022 | $19.4M | 3,222.05% |
| FY2021 | $585.0K | 6.56% |
| FY2020 | $549.0K | 449.00% |
| FY2019 | $100.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $72.9M | 0.24% |
| Jun 2026 | $72.8M | 0.23% |
| Mar 2026 | $72.6M | 0.22% |
| Dec 2025 | $72.4M | 0.22% |
| 21 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| CELC Celcuity, Inc. compare | $753.2M |
| TLX Telix Pharmaceuticals Limited compare | $575.9M |
| VKTX Viking Therapeutics, Inc. compare | $250.7M |
| VRDN Viridian Therapeutics, Inc. compare | $242.2M |
| DYN Dyne Therapeutics, Inc. compare | $213.5M |
| TARS Tarsus Pharmaceuticals, Inc. | $72.9M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $48.1M |
| DNLI Denali Therapeutics Inc. compare | $5.4M |
| ELVN Enliven Therapeutics, Inc. compare | $445.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on TARS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement